Status In progress
Process STA
ID number 807

Provisional Schedule

Expected publication 24 January 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Takeda UK (ixazomib citrate)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Leukaemia CARE
  Myeloma UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  UK Myeloma Forum

Commentators

Comparator companies Celgene
  Novartis
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
26 October 2017 Committee meeting: 3
05 September 2017 - 26 September 2017 Appraisal consultation
26 July 2017 Committee meeting: 2
27 April 2017 - 19 May 2017 Appraisal consultation
17 May 2017 Following the release of the appraisal consultation document (ACD) on 20 April 2017, the company, Takeda, requested to submit additional evidence. It has been agreed that this additional evidence will be accepted, in line with the guide to the process of technology appraisal, section 3.7.29. We will be unable to have this additional evidence reviewed by in time for the May 2017 technology appraisal committee meeting, therefore we are cancelling this discussion. We will reschedule this discussion and provide an update in due course.
29 March 2017 Committee meeting: 1
11 October 2016 Ixazomib has now received a positive CHMP opinion and this appraisal has been rescheduled back into the work programme. We are inviting consultee organisations to make evidence submissions by the new deadline of 5pm on 14 December 2016.
24 March 2016 Invitation to participate
22 March 2016 Draft scope documents
15 March 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance